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Introduction: Smoking is a well-established risk factor for rheumatoid arthritis (RA), and it has been proposed that
smoking-induced citrullination renders autoantigens immunogenic. To investigate this mechanism, we examined
human lung tissue from 40 subjects with defined smoking status, with or without chronic obstructive pulmonary
disease (COPD), and control tissues from other organs for citrullinated proteins and the deiminating enzymes
peptidylarginine deiminase type-2 (PAD2) and -4 (PAD4).
Methods: Lung tissue samples, dissected from lobectomy specimens from 10 never smokers, 10 smokers without
airflow limitation, 13 COPD smokers and eight COPD ex-smokers, and control tissue samples (spleen, skeletal
muscle, liver, ovary, lymph node, kidney and heart), were analysed for citrullinated proteins, PAD2 and PAD4 by
immunoblotting. Citrulline and homocitrulline residues in enolase and vimentin were analysed by partial purification
by gel electrophoresis followed by mass spectrometry in 12 of the lung samples and one from each control tissues.
Band intensities were scored semi-quantitatively and analysed by two-tailed Mann-Whitney T-test.
Results: Within the lung tissue samples, citrullinated proteins, PAD2 and PAD4 were found in all samples, with an
increase in citrullination in COPD (P = 0.039), but minimal difference between smokers and non-smokers (P = 0.77).
Citrullination was also detected at lower levels in the tissues from other organs, principally in lymph node, kidney
and skeletal muscle. Mass spectrometry of the lung samples showed that vimentin was citrullinated at positions 71,
304, 346, 410 and 450 in non-smokers and smokers both with and without COPD. A homocitrulline at position 104
was found in four out of six COPD samples and one out of six non-COPD. Citrulline-450 was also found in three of
the control tissues. There were no citrulline or homocitrulline residues demonstrated in α-enolase.
Conclusions: We have shown evidence of citrullination of vimentin, a major autoantigen in RA, in both non-smokers
and smokers. The increase in citrullinated proteins in COPD suggests that citrullination in the lungs of smokers is
mainly due to inflammation. The ubiquity of citrullination of vimentin in the lungs and other tissues suggests that
the relationship between smoking and autoimmunity in RA may be more complex than previously thought.* Correspondence: patrick.venables@kennedy.ox.ac.uk
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Rheumatoid arthritis (RA) is a true autoimmune disease
driven by anti-citrullinated peptide/protein antibodies
(ACPA) [1]. ACPA may be detected in RA serum more
than 10 years before onset of disease, suggesting that
the autoimmune response begins outside the joint [2].
In established disease, ACPA are strongly associated
with smoking and the shared epitope, with antibodies to
citrullinated α-enolase peptide 1 (CEP-1) and citrulli-
nated vimentin giving the highest odds ratios [3]. This
suggests that citrullinated enolase and vimentin in the
lung could prime the autoantibody response.
It is widely thought that alterations in protein structure
and antigenicity, resulting from the post-translational modi-
fication of arginine to citrulline, may break tolerance to
citrullinated proteins and drive an autoantibody response,
which eventually leads to disease [1,4]. Citrullination is me-
diated by peptidylarginine deiminases (PADs), of which
PAD2 and PAD4 are likely to be most important in RA [5].
Because smoking is a risk factor for RA [6,7], it has been
suggested that smoke inhalation may increase the concen-
tration of the PADs, which in turn leads to increased for-
mation of citrullinated proteins driving an ACPA response.
Although this is a simple and widely quoted hypothesis, the
evidence in its support is derived from one study in which
bronchoalveolar lavage (BAL) cells showed a modest in-
crease in the concentration of PAD2 and citrullinated pro-
teins from smokers [8]. However, the same study showed
constitutive expression of citrullinated proteins within
bronchial mucosal biopsy samples in healthy lung tissue
from both smokers and non-smokers.
In this study, we investigated surgically excised samples
of human lung from patients without RA (n = 41), in
whom smoking history and presence or absence of chronic
obstructive pulmonary disease (COPD) were accurately
documented (Additional file 1: Table S1). The documenta-
tion of COPD is important, because pulmonary inflamma-
tion is amplified [9], and persists despite smoking cessation
[10]. To test the organ-specificity of citrullination, we have
also analysed surgically excised samples of other human
tissues (lymph node, liver, kidney, spleen, ovary, heart and
skeletal muscle, n = 24). The samples were from surgery
providing sufficient material for immunoblotting [9], which
allows for more specificity when using some of the avail-
able antibodies to PAD2 and PAD4 [11], and the anti-
modified citrulline (AMC) kit for examining citrullinated
proteins. By these means we have examined the expression
of citrullinated antigens and the PAD enzymes, and their
relationship to COPD and smoking.
Methods
Lung samples
Lung tissue was carefully excised from lobectomy speci-
mens removed from patients diagnosed with solitarypulmonary lesions, mostly lung tumours (n = 41). Only
uninvolved lung tissue, at maximal distance from the lung
tumour, has been used for the current study. All patients
attended Ghent University Hospital and samples were
donated with informed consent and approval from the
Medical Ethics Committee (Belgium registration number:
B670201110668). Based on spirometry, according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines, and smoking history, patients were di-
vided into four groups: smokers with (n = 13) and without
(n = 10) COPD, ex-smokers with COPD (n = 8) and never
smokers without COPD (n = 10). For details of the study
subjects see Additional file 1: Table S1. The lung tissue was
homogenised in RIPA buffer with protease inhibitors, cen-
trifuged and the supernatants used for further experiments.
Control tissue samples from other organs
Uninvolved surgically removed human tissue samples
(spleen (n = 5), skeletal muscle (n = 2), liver (n = 4), ovary
(n = 4), lymph node (n = 4), kidney (n = 4) and heart
(n = 1)) were provided by Imperial College Healthcare
NHS Trust Tissue Bank with appropriate informed con-
sent and ethical approval (Imperial College Healthcare
Tissue Bank HTA licence: 12275; and Research Ethics
Committee Wales approval: 12/WA/0196). These control
tissues were homogenised as described above.
Immunoblotting and quantification
Lung and control tissue lysates (20 μg/sample) were re-
solved on 4 to 12% Bis-Tris NUPAGE gels (Invitrogen,
Carlsbad, CA, USA), transferred to nitrocellulose mem-
branes (Invitrogen) and western blotted using a stand-
ard protocol.
The following primary antibodies were used: rabbit
anti-fibrinogen (1:5,000; Calbiochem, San Diego, CA, USA),
rabbit anti-PAD2 (1:500; Abcam, Cambridge, UK), goat
anti-PAD4 (1:800; Abcam), rabbit anti-vimentin (1:1,000;
Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-
CEP1 (1:10,000; in house,[12]) and AMC antibody (Merck
Millipore, Darmstadt, Germany, according to the manufac-
turer’s instructions). All secondary antibodies were horse-
radish peroxidase (HRP)-conjugated and diluted 1:5,000.
Recombinant PAD2, PAD4, and in vitro citrullinated
recombinant α-enolase were used as positive controls
where needed.
Band intensities were quantified semi-quantitatively by
three independent individuals using a four point (0 to 3)
scoring method. The mean and median scores were ana-
lysed by statistical software GraphPad Prism (GraphPad
Software, La Jolla, CA, USA).
Statistics
Statistical differences between intensity scores in each lung
group were calculated by either one-way analysis of
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by two-tailed Mann-Whitney T-test using GraphPad Prism
software. A value of P <0.05 was considered significant.
Mass spectrometry
Representative tissue lysates from 12 lung samples and
one sample from each of the control tissues were se-
lected according to their levels of citrullination on the
AMC blots. A 5 mm band in the region of 52 kiloDal-
tons (kDa) was excised from a Coomassie-stained gel
and used for mass spectrometry analysis. Sample prepar-
ation was performed as described previously [13]. Briefly,
proteins were reduced with dithiothreitol and alkylated
with iodoacetamide before being digested with trypsin
(Promega, Madison, WI, USA) and injected into a nLC-
MC/MC workflow (Q Exactive mass spectrometer coupled
with a Dionex Ultimate 3000 UPLC; Dionex, Sunnyvale,
CA, USA). Samples were desalted online (PepMAP C18,
300 μm × 5 mm, 5 μm particle; Thermo Fisher Scientific,
Waltham, MA, USA) for 1 minute at a flow rate of 20 μl/
min and separated on a nEASY column (PepMAP C18,Figure 1 Citrullinated proteins are found in all lung tissue lysates. (A)
(20 μg/lane) from lung tissue lysates of four never smokers and six COPD s
and run on a single-welled SDS-PAGE gel. Each blot was cut into four strip
(Fib), citrullinated proteins (AMC), CEP-1 and vimentin (Vim)) with their corr
were aligned with the molecular weight markers (kDa). The results shown
(iii) smoker without COPD. (C) The intensity of citrullinated proteins in each
a 4-point scale (0 to 3) (arbitrary units (AU)). The bar diagrams represent m
AMC, anti-modified citrulline; CEP-1, citrullinated α-enolase peptide 1; COPD75 μm× 500 mm, 2 μm particle; Thermo Fisher Scientific)
over 60 minutes using a gradient of 2% to 35% acetonitrile
0.1% acid at 250 nl/min. Survey scans were acquired at a
resolution of 70,000 at 200 m/z and the 15 most abundant
precursors were selected for high-energy collision dissoci-
ation (HCD) fragmentation. Mass spectrometry data was
analysed in Peaks (V.6; Bioinformatics Solutions, Waterloo,
ON, Canada) using the post-translational modification
search option at mass tolerances of 10 ppm for MS1 and
0.05 Da for MS2 at 1% false discovery rate (FDR). Citrulli-
nated peptides were manually inspected when the citrulli-
nated residue produced a missed cleavage to exclude false
positive assignment of citrullination (that is deamidation or
the selection of the first isotopic peak as precursor mass).
Results
Citrullinated proteins are abundantly expressed in lung
tissue
Using the AMC antibody, citrullinated proteins were de-
tected in all lung samples examined (Figure 1A). There
were prominent bands near the 52 kDa marker, whichA representative immunoblot with the AMC antibody of proteins
mokers. (B) One lung sample from each patient group was selected
s that were used to determine presence of specific proteins (fibrinogen
esponding antibodies. The immunoblot strips for each lung sample
are three representative blots for a (i) non-smoker, (ii) COPD smoker,
lung sample was assessed by blinded semi-quantitative analysis using
ean ± standard error of the mean (SEM); NS, not statistically significant.
, chronic obstructive pulmonary disease; kDa, kiloDaltons.
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vimentin and part of fibrinogen (Figure 1B). The level of
citrullination from the AMC blots was scored semi-
quantitatively and showed that the patients with COPD
(current smokers and ex-smokers) had median scores of
2.0 compared with the non-COPD (smokers and never
smokers) who had median scores of 1.25. This difference
between the COPD groups and the non-COPD groups
reached statistical significance (P = 0.039), though there
was less difference between the smokers and non-smokers
combining COPD and non-COPD (mean score 1.90 vs
1.35; P = 0.46 vs P = 0.77) (Figure 1C). This suggests that
the increase in citrullination seen in the COPD groups
was more related to COPD itself, rather than to smoking.
When analysing other human tissues using the AMC
antibody, we detected the presence of citrullination in
some of the tissues, but with much lower intensity com-
pared with the lung samples (Figure 2A), suggesting,
amongst the tissues examined, that the lung is more
prone to citrullination.
PAD2, PAD4 and the RA antigens vimentin, fibrinogen
and enolase are present in lung tissue
PAD2 and PAD4 were mainly found in the lung, lymph
node, spleen and skeletal muscle, unrelated with the























Figure 2 Citrullination occurs in several human organs.
Representative immunoblot with (A) AMC, (B) anti-PAD2 and
(C) anti-PAD4 antibodies on proteins (20 μg/lane) from one COPD
lung tissue lysate (lane 1) and control tissue lysates from lymph
node (lane 2), liver (lane 3), kidney (lane 4), spleen (lane 5), ovary
(lane 6), heart (lane 7) and skeletal muscle (lane 8). AMC, anti-modified
citrulline; COPD, chronic obstructive pulmonary disease; PAD,
peptidylarginine deiminase.(Figures 2 and 3). Both enzymes were found in all of the
lung samples, with a marginal increase of PAD2 in the
smokers (Figure 3). However, this did not reach statis-
tical significance.
In the absence of commercially available antibodies to
citrullinated vimentin and fibrinogen, we used antibodies
to the native proteins, which also react with citrullinated
forms of the proteins. For enolase, we have used an anti-
body raised against the CEP-1 peptide, which reacts 100-
fold more sensitively with citrullinated enolase than with
the native molecule [11]. As expected, vimentin, as a ubi-
quitous cellular protein, and fibrinogen, as a prominent
protein in serum and extracellular fluid, were detected in
all of the samples, as was enolase, as a highly multifunc-
tional conserved protein.
Mass spectrometry to determine the dominant
citrullinated proteins in the lung
Representative tissue lysates were selected from 12 of
the lung samples and one sample from each of the other
tissues for characterisation of RA antigens by mass spec-
trometry. Citrullinated peptides were inspected for valid-
ity of site assignment (Additional file 2: Figures S1-S7).
Gel slices from an approximate 50 kDa region were ex-
cised for digestion and peptide sequencing, because this
was the area of maximum citrullination (Figure 1B). In this
region α-enolase and vimentin were the two most abun-
dant proteins identified. Sequence coverage for vimentin
was 97% and 95% for α-enolase in the combined samples.
We identified five citrullinated vimentin peptides with cit-
rullines at positions 71, 304, 346, 410 and 450 in the lung
samples from the non-smokers and smokers with and
without COPD (Table 1 and Additional file 2: Figures
S1-S6). We detected two citrullinated vimentin peptides
in other human tissues (citrulline at positions 304 and
450), both shared with the lung samples (Table 1).
Citrulline-304 was found in kidney, ovary and spleen
and citrulline-450 in kidney, ovary and lymph node.
Alpha enolase peptides were only detected in their na-
tive non-citrullinated form including arginines at posi-
tions 9 and 15 corresponding to the citrulline residues
in the immunodominant CEP-1 peptide [12].
We also detected one vimentin peptide with a homoci-
trulline residue (Table 1 and Additional file 2: Figure S7)
in four of six COPD samples and in one of the never
smokers (one out of three). No homocitrullines were de-
tected in α-enolase.
Discussion
We have shown the expression of citrullinated proteins
and the presence of citrullinating enzymes PAD2 and
PAD4 in lung tissue of both smokers and non-smokers.
Lower levels of citrullination were seen in lymph node,





















Figure 3 PAD2 and PAD4 are present in all lung tissues. Representative immunoblots with (A) anti-PAD2, and (B) anti-PAD4 of lung lysates
(20 μg/lane) from never smokers (n = 5), smokers without COPD (n = 5), COPD smokers (n = 6) and COPD ex-smokers (n = 3). COPD, chronic
obstructive pulmonary disease; PAD, peptidylarginine deiminase.
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presence of PAD2 and citrullination in the smokers, but
in our study, this was mainly associated with COPD ra-
ther than smoking itself. Given that pulmonary inflam-
mation is amplified in patients with COPD, our study
highlights inflammation in the lung as a likely basis for
epidemiological associations between smoking and the
ACPA response in RA.
The importance of inflammation rather than smoking
itself is supported by the finding that bronchiectasis, one
of the most severe infectious disease of the lung, is also
a risk factor for ACPA-positive RA, and that this risk is
independent of smoking [14,15]. Citrullination resulting
from inflammation has also been reported in organs other
than the lungs. Indeed, citrullination detected by immuno-
histochemistry in synovium, muscle and colon was roughly
in proportion to the amount of inflammation present in
these tissues [16]. Periodontitis, often cited the commonest
chronic infectious disease of humans, is another smoking-
independent environmental risk factor for RA [17], and
shows that the inciting inflammatory response does not ne-
cessarily have to begin in the lung.
A potential criticism of our study is that the pathology
for which the lobectomies were performed might have
influenced the citrullination in the samples examined.
Most of the samples were from patients with lung tu-
mours, which being judged as resectable, were focal, not
treated with chemotherapy, surrounded by a good margin
of unaffected tissue [9] and with the study sample taken as
far away from the primary lesion as possible. Moreover, it
is well known that citrullination associated with inflamma-
tion usually occurs immediately adjacent to inflammatory
infiltrates [16]. Therefore, we can conclude that the path-
ology distant from the sample of lung examined is unlikely
to have affected the results in our study.
Using mass spectrometry, we found that vimentin was
citrullinated at positions 71, 304, 346, 410 and 450 in
non-smokers and in smokers with and without COPD.A lower frequency of citrullinated vimentin peptides (cit-
rulline-450 and -304) was found in other human tissues,
which suggests that citrullination of vimentin is ubiquitous
in healthy tissues. A recent report also found citrulline-450
to be expressed in both the lungs and the synovial mem-
brane of patients with RA [18] and it was suggested that it
represented a shared immunological target between the
lungs and the joints. Our data does not contradict this con-
clusion, but does show that the lungs and the joints are not
unique in this respect. The ubiquity of citrulline-450 also
questions how important smoking is in relation to the ex-
pression of this residue.
Another citrullinated residue in our study, citrulline-
71, has not been previously described in lung tissue. Like
citrulline-450 we found it to be apparently independent
of both smoking and COPD, though firm conclusions
must be tempered by the small number of tissue samples
examined. Unlike citrulline-450, we did not find citrulline-
71 in any of our control tissues and therefore it seemed to
be lung-specific. This epitope is of particular interest be-
cause a peptide derived from vimentin (amino acids 66-
77), containing citrulline-71 and with leucine-70 replaced
by alanine, binds with high affinity to HLA-DRB1*0401
MHC class II molecules, eliciting T cell activation [19]. In
a more recent study, very similar vimentin-derived pep-
tides (amino acids 59-78), also containing citrulline-71,
bound to the same MHC class II molecules and to specific
T cells in both RA and healthy individuals [20]. Further-
more, this peptide activated T cells in citrullinated vimen-
tin peptide-immunised DR4 transgenic mice. Citrulline-71
is also part of an immunodominant B cell epitope [21],
which was demonstrated, in a recent large study, to react
with 37% of RA patients [3]. Our findings of ubiquitous
expression of citrulline-71, together with T cell binding re-
ported in a previous study [20] in both healthy people and
patients with RA, makes it difficult to argue that this epi-
tope is responsible for breaking tolerance leading to a
disease-specific ACPA response.
Table 1 Citrullinated (cit) and homocitrullinated (Hcit) vimentin peptides identified in human tissue samples
Vimentin peptides Frequency of detection
Lung Lymph
node









Citrullinated 70 L(cit)SSVPGVR78 / 71(cit)SSVPGVR78 2/4 1/2 2/3 2/3 0/1 0/1 0/1 0/1 0/1 0/1 0/1
295FADLSEAAN(cit)NNDALR310 0/4 0/2 1/3 0/3 0/1 0/1 1/1 1/1 1/1 0/1 0/1
344QM(cit)EMEENFAVEAANYQDTIGR365 0/4 0/2 1/3 0/3 0/1 0/1 0/1 0/1 0/1 0/1 0/1
403LLEGEES(cit)ISLPLPNFSSLNLR424 1/4 0/2 1/3 1/3 0/1 0/1 0/1 0/1 0/1 0/1 0/1
446TVET(cit)DGQVINETSQHHDDLE466 1/4 0/2 2/3 2/3 1/1 0/1 1/1 0/1 1/1 0/1 0/1
Homocitrullinated 101TNE(Hcit)VELQELNDRFANYIDKVR122 2/4 2/2 1/3 0/3 0/1 0/1 0/1 0/1 0/1 0/1 0/1
Representative tissue lysates from 12 lung tissues (COPD smokers (n = 4), COPD ex-smokers (n = 2), never smokers (n = 3) and smokers without COPD (n = 3)) and one from each of the control tissues were analysed by
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lead to tolerance breakdown, the question then arises
how does citrullination caused by inflammation break
tolerance at all? One possible answer is that citrullina-
tion is not important, at least not in the initial stages of
the generation of the ACPA response. Two studies have
recently shown that patients with periodontitis, a known
risk factor for RA, have a significantly elevated ACPA
response, but strikingly this is not citrulline specific
[22,23]. In a provisional report, we have found a similar
pattern in patients with bronchiectasis [24]. The same
pattern was also recently demonstrated by Brink et al.
[25] where antibodies against arginine-containing pep-
tides from RA autoantigens antedated development of
citrulline-specific ACPA in serum samples taken from
individuals years before they went on to develop symp-
tomatic RA. The importance of uncitrullinated antigens in
breaking tolerance, may well be supported by the fact that
α-enolase was only found in its native, non-citrullinated
form in lung tissues both from our study and in a previous
report [18]. A mechanism for tolerance breakdown could
be due to the fact that the immunodominant peptide of
α-enolase (amino acids 5–21) comes from its most evolu-
tionarily conserved region, including sequence homologies
with bacterial enolases of >90% [26]. We have previously
demonstrated cross-reactivity between human α-enolase
and Porphyromonas gingivalis enolase [12] and it is highly
likely that other bacterial enolases such as those expressed
in the microbiome of the lung could have similar cross-
reactivity leading to tolerance breakdown in the lung due
to association with infective exacerbations of COPD or
other chronic lung diseases.
Another possibility for tolerance breakdown in the lung
are carbamylated peptides as they have been linked to in-
flammation and smoking [27], and can activate T cells in a
MHC class II-dependent way [28]. Carbamylated lysine
residues give rise to homocitrulline, which is structurally
very similar to citrulline and is also recognised by ACPA
and by the detection kit for citrullinated proteins (the
AMC method) used in ours and other studies [29]. The
detection of a homocitrulline residue in vimentin at pos-
ition 104 in four out of six COPD samples and one out of
six non-COPD may explain the apparent increase of
citrullination shown by AMC in COPD in our study. More
importantly, a higher expression of carbamylated peptides
in pulmonary inflammation, such as COPD, could then
break tolerance to citrullinated proteins, by acting as neoe-
pitopes in the context of inflammation.
Conclusions
We have shown that citrullination in the lung is highly
abundant, with a modest increase induced by amplified
inflammation in the context of COPD. To explain the
citrulline specificity of autoimmunity in RA, we suggesta two-stage process in the evolution of the mature
ACPA response. In an initial phase, antibodies to native
proteins (such as enolase) may be induced by molecular
mimicry between bacterial and self-antigens in susceptible
individuals. Other mechanisms must be invoked for the
early induction of antibodies to vimentin or fibrinogen, as
neither have orthologues in bacteria. Epitope spreading to
their citrullinated counterparts could be explained, in the
case of vimentin, due to the ubiquitous expression of
major citrullinated epitopes in the lung, resulting in the
production of ACPA. Clearly, investigation of the two-
stage hypothesis requires additional work, involving the
evolution of very early autoantibody response in pa-
tients destined to get RA, through to the citrulline spe-
cificity of ACPAs, once the disease has evolved into its
full clinical expression.
Additional files
Additional file 1: Table S1. Characteristics of study subjects for lung
tissue analysis.
Additional file 2: Figures S1-S7. MS/MS spectra of seven vimentin
peptides. Citrullination of vimentin [UniProt:P20152] in positions 71, 304,
346, 410 and 450, and homocitrullination in position 104. The MS/MS
spectrum of tryptic peptides 70 L(cit)SSVPGVR78, 71(cit)SSVPGVR78,
295FADLSEAAN(cit)NNDALR310, 344QM(cit)EMEENFAVEAANYQDTIGR365,
403LLEGEES(cit)ISLPLPNFSSLNLR424, 446TVET(cit)DGQVINETSQHHDDLE466,
101TNE(Hcit)VELQELNDRFANYIDKVR122 are shown, where cit refers to the
citrullinated position and Hcit to the homocitrullinated position. The
matched fragment ions of the y-type (red) and b-type (blue) are shown. The
MS/MS spectrum in the bottom panel indicates matches of predominant
fragment ions to the peptide sequence.
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